An Immune-Based, Chemo-Free Option For DLBCL
- Early clinical data from a newly reported phase II chemolight R-Pola-Glo study suggest that immune-based combinations may provide durable, chemotherapy-free disease control for elderly and medically unfit DLBCL patients, an underserved population who often cannot tolerate even mini-R-CHOP.
- This phase II study tested R-Pola-Glo in elderly or otherwise unfit patients with newly diagnosed DLBCL (median age 80), addressing a critical need beyond R-CHOP-based therapy.
- Response rates remained high (96% at cycle 2; 90% at end of treatment), with CMR rising to 81% due to frequent late conversions during glofitamab consolidation.
- At 15 months’ median follow-up, 1-year PFS, EFS, and OS were 85%, 82%, and 90% respectively, with consistent benefit across geriatric risk groups and adverse prognostic features.
- Most patients completed therapy, with expected toxicities; CRS was mostly low-grade (31%), ICANS was rare (4%), and serious infections occurred in 22%, highlighting feasibility with careful supportive care.
The treatment of diffuse large B-cell lymphoma (DLBCL) in elderly patients and others unfit for chemotherapy remains a major clinical challenge. While standard anthracycline-based chemo-immunotherapy cures a substantial proportion of fit patients, many older individuals are unable to tolerate these regimens because of frailty, comorbidities, or cardiac risk.
“DLBCL cure rates and success are much better in younger, fitter patients than they are in older patients. For older patients, diffuse large B-cell lymphoma is much more challenging to treat because they don’t tolerate full-dose chemotherapy, and this remains a high unmet medical need,” Dr. Catherine Diefenbach, Director of the Clinical Lymphoma Program at NYU Perlmutter Cancer Center, tells SurvivorNet Connect.
The phase II R-Pola-Glo study was designed to combine complementary antibody-based mechanisms without conventional cytotoxic chemotherapy with rituximab, polatuzumab vedotin, and the bispecific agent glofitamab. This strategy aims to maximize tumor control while minimizing systemic toxicity.
Study Design & Patient Population
The phase II single arm trial enrolled previously untreated patients with aggressive B-cell lymphoma who were deemed elderly, frail, or medically unfit for standard chemo-immunotherapy. The median age was approximately 80 years, with most patients classified as unfit based on geriatric assessment.
A high proportion of these patients presented with advanced-stage disease and adverse clinical features. Treatment consisted of rituximab and polatuzumab vedotin combined with step-up dosing of glofitamab, followed by glofitamab consolidation.
Efficacy Outcomes
Efficacy data reported in the Blood ASH Supplement demonstrated high activity in this high-risk cohort. The overall response rate (ORR) was 90%, with complete metabolic response (CMR) increasing over time to 81% at end of treatment.
Notably, delayed conversions from partial to complete response were observed during later treatment phases, consistent with ongoing immune-mediated disease control from sustained bispecific antibody exposure. With a median follow-up of approximately 15 months, the 12-month progression-free survival (PFS) was 85% and overall survival (OS) was 90%, outcomes that compare favorably with historical data in elderly and medically unfit populations treated with reduced-intensity chemotherapy.
“The overall response rate in this patient population was extremely high… and that’s with no chemotherapy in an elderly and unfit population,” Dr. Diefenbach explains.
Safety & Tolerability
The safety profile of R‑Pola‑Glo was consistent with expectations for antibody-based and bispecific therapies. Cytokine release syndrome (CRS) occurred in 31% of patients, mostly grade 1-2, with one grade 3 event, and was managed with standard step-up dosing and supportive care.
Immune effector cell associated neurotoxicity syndrome (ICANS) was seen in about 4% of patients, including some grade 2-3 events. Grade 3-5 infections occurred in about 22% of patients, including three fatal infections, reflecting both treatment‑related immunosuppression and the intrinsic vulnerability of this elderly and frail cohort.
These findings highlight the importance of careful patient selection, infection prophylaxis, close monitoring, and treatment delivery in centers experienced with bispecific antibody therapy. Importantly, “there were not any unusual safety signals seen with this combination,” Dr. Diefenbach says.
Clinical Implications & Future Directions
This regimen represents a potentially transformative option for patients who have historically been excluded from curative-intent therapy. The ability to achieve deep and durable responses without conventional chemotherapy is particularly compelling for patients with cardiac disease or severe frailty. The observation of delayed complete responses further supports the biological rationale for extended immunotherapy-based treatment in aggressive lymphoma.
Despite these promising results, the study was single-arm and non-randomized, limiting direct comparison with established standards such as R-mini-CHOP or Pola-R-CHP. Follow-up remains relatively short, and longer observation is required to assess long-term durability, late relapses, and cumulative toxicity. Additionally, while chemotherapy is avoided, the regimen is not without risk, and careful patient selection and supportive care remain essential. Although small and non-randomized, the study provides an important proof of concept.
“This was a small study and a single-arm study, so it cannot be considered definitive,” Dr. Diefenbach says, “but it is a very intriguing chemotherapy-free safety and efficacy signal … [this] will hopefully generate interest in larger and more definitive studies for elderly and unfit patients with DLBCL, which is a huge unmet medical need.”
